Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Analysts' Corner
NEW YORK, September 24, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Johnson & Johnson (NYSE: JNJ), Bristol-Myers Squibb Company (NYSE: BMY), Merck & Co. Inc. (NYSE: MRK) and AbbVie Inc. (NYSE: ABBV). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Pfizer Inc. Research Report
On September 19, 2013, Pfizer Inc. (Pfizer)'s stock declined 0.7% to end the day at $28.84, compared to the previous day's closing price of $29.04. During the day, the price fluctuated between $28.65 and $29.15. On the previous day, September 18, 2013, the stock touched a high of $29.27, the highest reached in over a month. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d702_PFE]
Johnson & Johnson Research Report
On September 12, 2013, The New York Times published a report which stated that Johnson & Johnson (J&J) has announced two recalls of well-known products in the gap of a week. As per the report, the Company's pharmaceutical unit, Janssen, informed doctors and patients on September 11, 2013 that it was recalling one lot of Risperdal Consta, an injectable antipsychotic treatment, after routine testing turned up evidence of mold; while last week, J&J recalled 200,000 bottles of liquid Motrin for infants due to the speculations of it containing tiny particles of plastic. The report mentioned that in both cases, the recalls involved products or ingredients that were made by external companies and the risk to patients was low. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/07a8_JNJ]
Bristol-Myers Squibb Company Research Report
On September 19, 2013, Bristol-Myers Squibb Company (Bristol Myers)'s stock rose 2.2%, from its previous day's closing of $46.52. The days' closing price of $47.53 has been the Company's highest in over 3 months. Also, during the day, the stock fluctuated from $46.38 to $47.58. The Full Research Report on Bristol-Myers Squibb Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/81a9_BMY]
Merck & Co. Inc. Research Report
On September 19, 2013, Merck & Co. Inc. (Merck)'s stock declined 0.3% to $48.26, from its previous day's closing price of $48.40. The stock fluctuated from $48.10 to $48.49. The broad market index, S&P 500 also declined 0.2% during the day. The Full Research Report on Merck & Co. Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/430d_MRK]
AbbVie Inc. Research Report
On September 19, 2013, AbbVie Inc. (AbbVie) announced that its Board of Directors has authorized a quarterly cash dividend in the amount of $0.40 per share. AbbVie informed that the cash dividend is payable on November 15, 2013 to stockholders of record at the close of the business on October 15, 2013. The Full Research Report on AbbVie Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/273c_ABBV]
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.